CANF R&D Expenses
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares · R&D Expenses
CANF R&D Expenses
Latest reported$7.12Mperiod ending
CANF TTM R&D Expenses ($3.56M → $7.12M)
TTM R&D Expenses
High-resolution chart · PNG
CANF r&d expenses history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | R&D Expenses (USD) |
|---|---|
| 7,115,000 | |
| 6,904,000 | |
| 6,693,000 | |
| 6,299,500 | |
| 5,906,000 | |
| 5,831,500 | |
| 5,757,000 | |
| 5,588,000 | |
| 5,451,000 | |
| 5,364,500 | |
| 5,983,000 | |
| 7,170,000 | |
| 7,907,000 | |
| 8,003,000 | |
| 7,763,000 | |
| 8,410,000 | |
| 9,313,000 | |
| 10,368,000 | |
| 9,850,000 | |
| 9,645,000 | |
| 8,707,000 | |
| 9,483,000 | |
| 11,951,000 | |
| 13,015,000 | |
| 14,070,000 | |
| 13,304,000 | |
| 10,976,000 | |
| 9,035,000 | |
| 7,397,000 | |
| 6,205,000 | |
| 6,075,000 | |
| 5,729,851 | |
| 5,375,573 | |
| 5,345,963 | |
| 5,271,606 | |
| 5,561,010 | |
| 6,027,024 | |
| 6,238,330 | |
| 6,078,092 | |
| 5,532,500 | |
| 4,919,427 | |
| 4,345,916 | |
| 3,855,866 | |
| 3,222,908 | |
| 3,166,107 | |
| 3,656,369 | |
| 4,160,318 | |
| 4,940,303 | |
| 4,787,281 | |
| 4,490,740 | |
| 4,370,617 | |
| 3,974,328 | |
| 3,972,231 | |
| 3,484,455 | |
| 3,593,071 | |
| 3,203,177 | |
| 3,196,476 | |
| 3,470,618 | |
| 3,561,719 | |
| 3,477,605 | |
| 3,420,273 |